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disease; it includes disease which is either extensive within
the breast and/or in ipsilateral nodal areas. These cancers
vary widely in biological characteristics and clinical behavior,
ranging from locally aggressive but systemically ‘‘indolent’’, to
de novo generalised disease. LABC includes: (1) large breast tu-
mours (>5 cm in diameter); (2) cancers that involve the skin of
the breast or the underlying muscles of the chest; (3) cancers
that involve multiple local lymph nodes (those located in the
arm pit or the soft tissues above and below the collar bone)
and (4) inflammatory breast cancer (IBC). The clinical man-
agement of LABC is complex and should be tailored to the
individual patient, according to the biological features of the
disease. A multidisciplinary approach is recommended com-
bining systemic therapy (chemotherapy and/or hormone
therapy and biological agents) and in some cases radiother-
apy. LABC is reported to occur in 10–15% of all new primary
breast cancer diagnoses [1]. At least 20–30% of women with
breast cancer wait more than 8 weeks from the initial symp-
tom(s) until they seek clinical assessment [2,3]. Richards et al
reported a 12–19% decrease in 5-year survival in those women
with delays of 3 months or more versus those with a shorter
time to diagnosis [4]. The following factors have been cited
as causes of patient delay: poor access to health care, lack
of preventive health-care habits, increasing age, having child-
care/elder care obligations, notion that the symptoms are be-
nign, poor education, misperception of risk, embarrassment,
fear of chemotherapy and breast loss and concern about
being a hypochondriac and pessimist about survival [3–5,6].
IBC is an aggressive disease that progresses rapidly and car-
ries a very grim prognosis. It is characterised by erythema, ra-
pid enlargement of the breast, skin ridging and a
characteristic ‘‘peau d’orange’’ appearance of the skin sec-
ondary to dermal lymphatic tumour involvement. Although
a palpable tumour may not be present, about 55–85% of pa-
tients will present with metastases to the axillary or supracla-
vicular lymph nodes. Accurate diagnosis is criticallyimportant, as multimodal therapy can significantly improve
outcomes if instituted early enough. The treatment of LABC
is complex, and to complicate matters further, when it ap-
pears as a recurrent disease it can be considered as a ‘‘moving
target’’ since previous treatment delivered in the adjuvant set-
ting may affect treatment choice at recurrence.
Patients with stage IIIB or IIIC disease – including those
with IBC and those with isolated ipsilateral internal mam-
mary or supraclavicular lymph-node involvement – are often
inoperable. Patients with stage IIIB or IIIC disease who re-
spond to primary chemotherapy should be treated until the
response plateaus or to a maximum of six cycles (minimum
four cycles), after which several case series have demon-
strated that locoregional control is improved [7–12]. The loco-
regional management of patients with stage IIIC disease who
respond to chemotherapy is unclear and should be individu-
alised. In the absence of evidence on this subgroup of pa-
tients, it is reasonable that they receive locoregional
radiotherapy (including nodal irradiation). The role of com-
pletion mastectomy should be individualised and based on
technical and disease factors. Following the completion of
chemotherapy, pre- or postmenopausal patients with locally
advanced (operable and inoperable) hormone-responsive tu-
mours should receive endocrine therapy according to their
menopausal status. Patients with HER2-positive breast cancer
who received chemotherapy in combination with trast-
uzumab should receive trastuzumab maintenance therapy.
In the case of inflammatory breast cancer the role of anti-
angiogenic agents has been explored in either HER2-positive
or -negative disease. Inflammatory breast cancer is character-
ised pathologically by high vascularity and increased micro-
vessel density because of the high expression of angiogenic
factors such as vascular endothelial growth factor (VEGF).
Use of bevacizumab, a VEGF-targeting monoclonal antibody,
resulted in substantially improved progression-free survival
and response in patients with advanced breast cancer and
showed neoadjuvant activity in patients with previously un-
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study, neoadjuvant treatment with bevacizumab, trast-
uzumab and chemotherapy was efficacious and well tolerated
in patients with previously untreated primary IBC [13–15].
Treatment of LABC and IBC requires a coordinated multidisci-
plinary approach that should be individualised depending on
tumour characteristics and response to treatment. The treat-
ment may include a combination of chemotherapy, endocrine
therapy, biological therapy and radiotherapy. While the prog-
nosis in these cases is poor compared with that for other pre-
sentations of breast cancer, a reasonable survival and quality
of life can be obtained with a team approach to treatment. All
patients with LABC and IBC should be considered candidates
for clinical trials to evaluate the most appropriate fashion in
which to administer the various components of multimodal-
ity regimens.
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